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Resu/~: Lq~l measurements were: total chol~J~tefol (C) 219 ± 38 mg/dl, 
HDL.C 42 ± 11 mg/dl, LDL-C 146 ~: 35 rng/dl, Tnglycerldes 73 ~. 42 m~'dt, 
Lq0~! mo~lymg ll~a~y ~ ~ in 210 pat~e~m (33%) w~th 185 patients 
(29%) taking slatms or flbrat~ alone, Two of morn agents were u ,~ to med+ty 
Nrnmt ~ m 16 patttmlS (2.5%), Utlt¢i~l 1997 AlIA gu~lefines, 447 pat~ent~ 
(7o%) ~ requ~e furm~ ~ mod~r,g t~mpy as LOL.C ¢o~t~r~ 
Of I00 patmnls who had undmgone¢ofonaqf artery by l~ 9 ,~ng (CAOG), 
6~ MdaI~Um LOL.C ~130m0/dl ar~191 ipatle~ts had a sen~n LOI..C ~!00 
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B~rgmaz,~" 4HPMC) =s a semm/nlhe~ pelysa¢+ 
c~mde t~'m~ forum ~ ge~ m N 0mmmnemma, w ct. ~ .s  m=mtam 
! o ~  and lemsemalmn, The pu~¢~e t ~ ~ eoul~e-.l~m~ 
p~a~o-¢e,,W~ed study was ~ evsk~e ~e a~r~ of m~ee dine ~ of 
HPl~IC to feclu~ LO~ ct to~l~ m men a~:h,~¢~en with f f~ld-to-modera~ 
rmma~. ~ (Lm. ~ 130--,~0 mgtdL). 
Mea~01s.- N~r at least O weeks on a NabonaJ Cho~kml~ol ~ I~o- 
~ S~S~ I d,e~ tl~O imn=immm ,m~re ramlkm~ a==~r~ed Io ono of lout 
tmaueem arms: ~ 4cell, _,~,~) m ~ a~ doses ol 2.5 9 qd (w~h l~e 
moma~ meal), 2.5 9 I~L o~ 3.75 9 I~I fo+ a 6-~,~ek ~ l~nod. HPMC, 
m l>~,~c-,-ed fo~m was ~ mm an o ~  dnnk taken at n~al 
lime. 
Res~/~- LOL cho~eslen~ e-~x,,-,ses (~ ± SD) ~ -3.4 ± 8.0% 
(placebo), -6.7 :~ 10.2% (2.5 9 q~ P > 0.05 vs. placebo). -13.2 ± 12.0% 
42.5 g bid. p < 0.001 vs. ~ ) ,  a~d -11.9 ± 109% 4375 9 bid, p < 0.001 
vs. ~ ) .  No ~/',,~,~-~.~s between ~ were obsen~d for HDL cho~es- 
tem~ and teglycende n~0,mms, or me modenco of gmm0~,:s~,~ and omer 
advsme experiences. 
Co~ctusk~s.- M closes of 25 g b~d and 3.75 g I~dL HIP,¢~C was ~=11 tcterated 
and ~ re¢luced LDL ct~oh~eroL Ihus may be a useful a(~onct to da~1 
fo~ the management of nald-to-moderade ptm~anj t ~ e ~ e ~  
~ T e n  Yearn of Simvasiat~ Tre=Imenl in F.mpedem:e 
M=rked ~ 
A.G. OP, son. J. M+mgaatd+ De~o~Me~mmme & Cam. Facu~ o~ ~'~,a/~ 
~okgreur=d: HMGCoA reductase ml~ibdor5 (statms) are increasingly used 
to lower elmrated low density lqX)l~rOl~n (LDL) cholesterol ~ Io presumer 
corenary Oisease. Long*erm safety a~l elftcacy ~ata (morn than 5 years) are 
scarce ~ non-emsting f~ tt~ stattns. 
Melt~ls: Simvestatin was ~ for 120 mon~ to 57 patients (36 males) 
~th immary I ~  ol wltom 30 were ~ to ha~e fam~tml 
hypercholesterelemia. Treatment was given first as per protocol and after 
two veam as compassionate use+ Treatment was monitored by the same 
physicians and research nurse through the ten years from 1986 to 1996 at 
n =,.~nthly in,'ewals at start, then even/six month. Mean pat~=nt age at start was 
53 (range 30-74) years. 
Resutts: After 10 years 17 patients had dropped out+ Slmvastatm dose 
ranged from 10 to 60 mg daily. Mean body we+gl~l increased by 3 kg. Mean 
baseline total and LDL cholesterol were 310 ± 81 (SO) and 245 :E 76 moj'dt, 
respe~vely. Total and LOL cholesterol decreased immediately on simvastatin 
and stayed constantly at this low level through ttte 10 years. At 120 months 
plasma total and LDL cholesterol was 32 and 38% lower than baseline. The 
percentage number of patients reaching tl~e LDL targets of 200, 123 and 96 
mg/dl at 120 months were 85, 20 and 3, respectively. Szmvestatin was well 
tolerated subjectively dudng the whole trial length. Increases in s-ALAT and 
s-ASAT activities were seen at seldom occasions and evenly spread over the 
period of treatment. No CK-elevaUon 10x the upper normal imit was seen. No 
cases of myopathy were noted. 
Conclusion: Ten years of simvaststin treatment in marked hypercholes- 
temlemia show that the drag is an effective hypochctestemlemic agent with 
few subjective or objective side effects. The drag seems well suited for long 
term preventive use against coronary disease. 
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W~ h'w~t~gat~d th~ i ~  of Lova,~a~n an~ V~m~ E ~ 
t ,~  (~g~ ~ ~: O yearn, 11~ me~) who wxW~,mt C,~BO, PatW~ mcw~l  
L ~  (gfl~p t0 n =~ 3B) and ~ l m  plt~ V~n E (gRip 2, n =45) fo~ 
ve~x! t~ um~ ~ depe~ ~ me gene~ pmmm~ (m~up ~)+ 3+4 
graf~ (tOP internal mamma~ af1~y pMA| ~d ~OS veto g~)  m ~ 
b y ~  ~38,  ~amt  at 10e ± 8 we~ aae . ,~/ .  
~ :  Two yum a~ler m~lew, mere ~ a ~ m(Mmo, ot 
Cho~e,~,  t-DL.C an~ ~ n  B l~mm~en ~ 3 ~ (m ~ 
fo~ L~,<~: mdgctmn at mon~ 24), P!menls ol 9mups 1 and 2 ~ a e~fi~ 
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~ .  to pmoo~namty male Sublects. system¢ and ~ ~ 
rml dysfurctmn am essocmted wdh CAD a~dtor CAD ,sk factora. This a~,x.~- 
abort has not been slu0ied m wOmellL 
Me~maS: In 29 womon wfftt chest pare. the mtabom~ between coronary 
( ~  by quamtat~ com~W ang+ugrap~ ~ [~I )  =~ 
brach~ ~eW ([BA| ~gh ~mkmo~ =~a:~xJ  bekYe and a~r ~e.~ma)  
eedornef~l lurctinn was mBmmed. 
~ .  Mean age was 56.1 440-7"3) ~.  H~sto~y ot hypam~,--~;-~ on- 
¢u~ed in 62%. tot~:oo use 55%, ~ i a  55%, fame/~ C./~ 45% InK! 
cflabetes I0%. Coronary endom~ dysfuncth0n (fa~ure to dilate with/Oh) 
was foond m 79% (23r29) w~e BA e~dom~ ~ (no fk~'H~edl- 
atod o~ia~on) occum~ in only 31% (~I~), A,T,,~-,Cj women ~ BA endothelial 
~ .  55% (.5/9) also Pad coronary endomel~ ~ .  However, 
in women w~ normal BA ~-~,thel~al functmn only 10% (2/20) had nom~l 
coronary eedothet~al fur~to~. Thus, a conoo~nt brach~l and ~- ,a ry  e~- 
doff~lial respo~,lse was seen in octy 24% (7F29). 
Conc/us/on: In women with chest pain and muttiPte CAD risk 1actom. corn" 
nan/endomel~ m frequent (79%). ~ not ~ l y  ~ted  
w=th systemK: endothel~ d ~ .  Hence. the a...,u.;octatton bet'~L'e~ sys- 
temic and coronary endothelial funo~o~ in women may be different han m 
men. 
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Endothelial function is known to be impaired m chro~c smokem po~t f  by 
o~o/gen-dem,'ed flee radicals. [T, etary supplement of antioxiOant vitamins may 
prOwde protec0on against endoth~i;~=! dysfunction. To investigate whether 
